Oncotarget

Researchers Wafik S. El-Deiry and Shengliang Zhang discuss how the SARS-CoV-2 spike protein disrupts the p53 tumor suppressor pathway in cancer cells, potentially compromising its functions and increasing cancer cell viability. They highlight the need for further research to understand the implications of SARS-CoV-2 infection on cancer treatment outcomes.

Researchers Kevin C. Ma, Esther Mena, Liza Lindenberg, and others discuss their AI tool for producing PET images without CT scans, revolutionizing oncology patient imaging and reducing radiation exposure.

Researchers discuss how transfected SARS-CoV-2 spike DNA affects cancer cells' response to chemotherapy by interrupting p53-MDM2 interaction, suppressing p53 transcriptional activity, and inhibiting chemotherapy-induced activation of p21(WAF1) and TRAIL Death Receptor DR5.

The podcast discusses the Oncotarget sponsorship of the 19th International p53 Workshop in Italy, highlighting groundbreaking research on the TP53 gene in cancer. Distinguished speakers like Dr. Andre Gudkov, a collaborator with Oncotarget, contribute to advancing understanding of TP53 biology in oncology.

Exploring novel therapeutic bispecific antibodies for treating B-cell lymphoma by targeting IgM and other B-cell antigens. Discussing the challenges of antibody therapy due to the presence of soluble IgM in the blood and how bispecific antibodies can address this issue.

Exploring synergistic drug combinations targeting AML cells to enhance cytotoxic effects and overcome drug-resistance mechanisms. Research study shows promising results with ABT199 and Thyotepa, revealing enhanced apoptosis activation, DNA damage response, stress signaling, and reduced drug resistance markers. Potential for improved therapies for AML patients.

Exploring the role of MIA-602 in overcoming Doxorubicin-resistance in Acute Myeloid Leukemia, researchers examined the impact of MIA-602 on Doxorubicin-resistant AML cell lines. In vitro results revealed a significant reduction in cell viability for all treated cells, indicating potential alternative treatment for AML and drug-resistant AML with GHRH antagonists.

Researchers discuss the use of biomarkers in predicting response to paclitaxel in cancer therapy, emphasizing personalized medicine. They explore the SSR3 gene as a potential biomarker for paclitaxel susceptibility in cancer cells, highlighting its role in the unfolded protein response pathway and challenges in treating glioblastoma.

Researchers Haven R. Garber, Sreyashi Basu, Sonali Jindal, Zhong He, and Jennifer K. Litton discuss the feasibility and outcomes of using dual checkpoint inhibition with durvalumab and tremelimumab in HR+/HER2-negative breast cancer patients before surgery. The study showed mixed responses among patients, revealing both benefits and challenges of this treatment approach.

Researchers discuss the synergistic effects of ABT199/venetoclax and thiotepa in AML cells, showcasing enhanced apoptosis activation and DNA damage response. The combination shows promise in overcoming drug resistance and reducing pro-survival proteins in leukemia treatment.